Literature DB >> 9199964

A broad cytotoxic T lymphocyte response to influenza type B virus presented by multiple HLA molecules.

P A Robbins1, P A Rota, S Z Shapiro.   

Abstract

The HLA restriction and epitope specificity of cytotoxic T lymphocytes (CTL) involved in recovery from influenza type B infection have not been extensively characterized. Here lymphocytes obtained from a healthy individual contained virus-specific CTL restricted by class I HLA molecules, HLA-A1, A2, B7 and B8, and the class II HLA molecules, HLA-DR1 and DR3. Four conserved viral epitopes were predicted from allele-specific motifs for peptides interacting with HLA-B8 and HLA-DR1. Bulk CTL recognized three 9mer HLA-B8-restricted peptides from nucleoprotein, residues 30-38, 263-271 and 413-421, and a 13mer HLA-DR1-restricted peptide from hemagglutinin, residues 308-320. The epitopes presented by HLA-A1, HLA-B7 and HLA-DR3 remain undefined. Peptide-specific CTL lines recognized influenza type B virus-infected cells indicating the peptides are representative of naturally processed epitopes. A hemagglutinin peptide-specific CD4 CTL clone expressed approximately 200 molecules of perforin mRNA/cell, suggestive of a functional perforin pathway for target cell lysis. The results indicate a broad CTL response composed of both CD8 CTL and CD4 CTL recognizing viral epitopes presented by multiple HLA molecules.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9199964     DOI: 10.1093/intimm/9.6.815

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  9 in total

1.  Influenza B virus-specific CD8+ T-lymphocytes strongly cross-react with viruses of the opposing influenza B lineage.

Authors:  Carolien E van de Sandt; YingYing Dou; Stella E Vogelzang-van Trierum; Kim B Westgeest; Mark R Pronk; Albert D M E Osterhaus; Ron A M Fouchier; Guus F Rimmelzwaan; Marine L B Hillaire
Journal:  J Gen Virol       Date:  2015-04-21       Impact factor: 3.891

2.  The magnitude and specificity of influenza A virus-specific cytotoxic T-lymphocyte responses in humans is related to HLA-A and -B phenotype.

Authors:  A C M Boon; G de Mutsert; Y M F Graus; R A M Fouchier; K Sintnicolaas; A D M E Osterhaus; G F Rimmelzwaan
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

3.  Comparative analysis of evolutionary mechanisms of the hemagglutinin and three internal protein genes of influenza B virus: multiple cocirculating lineages and frequent reassortment of the NP, M, and NS genes.

Authors:  S E Lindstrom; Y Hiromoto; H Nishimura; T Saito; R Nerome; K Nerome
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

4.  A human CD4+ T cell epitope in the influenza hemagglutinin is cross-reactive to influenza A virus subtypes and to influenza B virus.

Authors:  Jenny Aurielle B Babon; John Cruz; Francis A Ennis; Liusong Yin; Masanori Terajima
Journal:  J Virol       Date:  2012-06-20       Impact factor: 5.103

5.  Structural basis for RNA binding and homo-oligomer formation by influenza B virus nucleoprotein.

Authors:  Andy Ka-Leung Ng; Mandy Ka-Han Lam; Hongmin Zhang; Jinhuan Liu; Shannon Wing-Ngor Au; Paul Kay-Sheung Chan; Jiahuai Wang; Pang-Chui Shaw
Journal:  J Virol       Date:  2012-04-11       Impact factor: 5.103

Review 6.  Influenza B: Prospects for the Development of Cross-Protective Vaccines.

Authors:  Liudmila M Tsybalova; Liudmila A Stepanova; Edward S Ramsay; Andrey V Vasin
Journal:  Viruses       Date:  2022-06-17       Impact factor: 5.818

7.  Human cytotoxic T-lymphocyte repertoire to influenza A viruses.

Authors:  J Jameson; J Cruz; F A Ennis
Journal:  J Virol       Date:  1998-11       Impact factor: 5.103

8.  Multiple genotypes of influenza B virus circulated between 1979 and 2003.

Authors:  Jonathan A McCullers; Takehiko Saito; Amy R Iverson
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

9.  Nucleoprotein vaccine induces cross-protective cytotoxic T lymphocytes against both lineages of influenza B virus.

Authors:  So-Young Lee; Jung-Ok Kang; Jun Chang
Journal:  Clin Exp Vaccine Res       Date:  2019-01-31
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.